Spondyloarthropathies News

Wednesday, August 22, 2007 PsA Patients May Benefit From Statin Therapy
New research linking PsA with subclinical atherosclerosis may point to a potential role for statin therapy in these patients…Gonzalez-Juanatey C, et al. Arthritis Rheum. 2007;57:1074-1080.

Wednesday, June 13, 2007 Stopping AS May Require Earlier Use of TNF-Inhibitors
Inflammation in AS stops once the subchondral bone is eroded and the bone/cartilage interface disappears, so preventing bone erosion and syndesmophyte formation is likely to require early anti-inflammatory treatment, including TNF-inhibitors...

Friday, May 25, 2007 Accumulating Evidence Supports Adalimumab for Severe Psoriatic Arthritis
Adalimumab (Humira®) is safe and effective for patients with active psoriatic arthritis (PsA) who showed an inadequate response to disease-modifying antirheumatic drugs (DMARDs)...

Wednesday, May 23, 2007 Celgene to Advance Clinical and Regulatory Development of Oral Anti-Inflammatory Agents Based on Successful Phase II Trial in Psoriasis; Expands Clinical Program to Include RA and PsA
Celgene Corp (SUMMIT, New Jersey), an integrated global biopharmaceutical company engaged in the discovery, development, and commercialization of novel therapies for the treatment of inflammatory diseases and cancer, announced plans to advance its leading oral anti-inflammatory candidates to address a broad range of inflammatory diseases...

Tuesday, April 03, 2007 Inflammation More Important Than Joint Damage in Psoriatic Arthritis Disability
Psoriatic arthritis disease activity is more important than joint damage in causing disability, especially in the early years of disease duration…

Thursday, January 25, 2007 Anti-Infliximab Antibodies Linked to Nonresponse in AS
New research outlines some drawbacks and limitations in the use of TNF-inhibitors among patients with ankylosing spondylitis (AS) and other forms of spondylarthritis...

Wednesday, December 06, 2006 Serum MMP-3 May Be Biomarker of Joint Damage in AS, MRI Accuracy Questioned
Measuring serum levels of metalloproteinase 3 (MMP3) may be an inexpensive yet accurate way for rheumatologists to predict which AS patients will develop joint damage, particularly in those with pre-existing radiographic damage...

Thursday, November 16, 2006 Abbott's HUMIRA (adalimumab) Approved in Canada for Treatment of Ankylosing Spondylitis
Abbott announced that it has received approval from Health Canada to market HumiraR (adalimumab) as a treatment for active ankylosing spondylitis (AS) in Canada.

Thursday, October 19, 2006 Access to TNF-Blockers Severely Limited in UK
Access to TNF-inhibitor treatment is limited even for British RA patients who meet official guidelines for treatment, and is even more limited for patients with psoriatic arthritis or  ankylosing spondylitis ... Kay, LJ, et al. Rheumatology. 2006 Oct 11; [Epub ahead of print].

Thursday, August 17, 2006 Early Diagnosis of AS: Dr. Rudwaleit Does the Math to Make It Easy
Diagnosing early ankylosing spondylitis in a patient with chronic back pain may be easier with a simple method based on standard tests and symptoms... Rudwaleit M, et al. Ann Rheum Dis. 2006;65:1251-1252.